TP53

Chr 17ADSomatic

tumor protein p53

Also known as: BCC7, BMFS5, LFS1, P53, TRP53

This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016]

Primary Disease Associations & Inheritance

{Adrenocortical carcinoma, pediatric}MIM #202300
AD
{Basal cell carcinoma 7}MIM #614740
AD
{Choroid plexus papilloma}MIM #260500
AD
{Colorectal cancer}MIM #114500
ADSomatic
{Glioma susceptibility 1}MIM #137800
ADSomatic
{Osteosarcoma}MIM #259500
Somatic
Bone marrow failure syndrome 5MIM #618165
AD
Breast cancer, somaticMIM #114480
Hepatocellular carcinoma, somaticMIM #114550
Li-Fraumeni syndromeMIM #151623
AD
Nasopharyngeal carcinoma, somaticMIM #607107
Pancreatic cancer, somaticMIM #260350
UniProtEsophageal cancer
UniProtSquamous cell carcinoma of the head and neck
UniProtLung cancer
UniProtPapilloma of choroid plexus
235
ClinVar variants
83
Pathogenic / LP
0.53
pLI score
12
Active trials
Clinical SummaryTP53
🧬
Gene-Disease Validity (ClinGen)
Li-Fraumeni syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.53) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
83 Pathogenic / Likely Pathogenic· 84 VUS of 235 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.47LOEUF
pLI 0.532
Z-score 3.26
OE 0.20 (0.100.47)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.98Z-score
OE missense 0.82 (0.730.92)
192 obs / 234.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.20 (0.100.47)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.82 (0.730.92)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.07
01.21.6
LoF obs/exp: 4 / 19.5Missense obs/exp: 192 / 234.3Syn Z: -0.54

ClinVar Variant Classifications

235 submitted variants in ClinVar

Classification Summary

Pathogenic58
Likely Pathogenic25
VUS84
Likely Benign59
Benign7
Conflicting2
58
Pathogenic
25
Likely Pathogenic
84
VUS
59
Likely Benign
7
Benign
2
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
45
2
11
0
58
Likely Pathogenic
15
4
6
0
25
VUS
11
56
15
2
84
Likely Benign
0
9
26
24
59
Benign
0
3
3
1
7
Conflicting
2
Total71746127235

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TP53 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

TP53-related Li-Fraumeni syndrome

definitive
ADLoss Of FunctionAbsent Gene Product
Cancer
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

TUMOR PROTEIN p53; TP53
MIM #191170 · *

{Adrenocortical carcinoma, pediatric}

MIM #202300

Molecular basis of disorder known

Autosomal dominant

{Basal cell carcinoma 7}

MIM #614740

Molecular basis of disorder known

Autosomal dominant

{Choroid plexus papilloma}

MIM #260500

Molecular basis of disorder known

Autosomal dominant

{Colorectal cancer}

MIM #114500

Molecular basis of disorder known

Autosomal dominantSomatic mutation

{Glioma susceptibility 1}

MIM #137800

Molecular basis of disorder known

Autosomal dominantSomatic mutation

{Osteosarcoma}

MIM #259500

Molecular basis of disorder known

Somatic mutation

Bone marrow failure syndrome 5

MIM #618165

Molecular basis of disorder known

Autosomal dominant

Breast cancer, somatic

MIM #114480

Molecular basis of disorder known

Hepatocellular carcinoma, somatic

MIM #114550

Molecular basis of disorder known

Li-Fraumeni syndrome

MIM #151623

Molecular basis of disorder known

Autosomal dominant

Nasopharyngeal carcinoma, somatic

MIM #607107

Molecular basis of disorder known

Pancreatic cancer, somatic

MIM #260350

Molecular basis of disorder known

📖
GeneReview available — TP53
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Endometrial NeoplasmsTP53 Gene MutationChromosomal Instability

Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma

NOT YET RECRUITING
NCT06521684Peking Union Medical College HospitalStarted 2024-09-01
Chronic Myeloid Leukemia, Chronic PhaseWithdrawal;Drug

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

ACTIVE NOT RECRUITING
NCT04147533Phase PHASE2Masaryk UniversityStarted 2020-06-16
Imatinib withdrawalDasatinibNilotinib
Li-Fraumeni SyndromeTP53 Gene MutationHereditary Cancer Syndrome

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

RECRUITING
NCT04541654Dana-Farber Cancer InstituteStarted 2020-09-15
Data and Specimen Collection
Pancreatic CystPancreas CystSerous Cystadenoma

Feasibility of Molecular Biology in Pancreatic Cyst Tumors

ACTIVE NOT RECRUITING
NCT03305146Phase NAHospital St. Joseph, Marseille, FranceStarted 2017-01
Molecular biology analysis of pancreatic intra-cyst fluid
Gastric CancerHealthy

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

RECRUITING
NCT05991947Zhejiang Cancer HospitalStarted 2021-03-01
No intervention
Li-Fraumeni SyndromeNeoplasmsTp53 Mutations

Clinical and Genetic Studies of Li-Fraumeni Syndrome

RECRUITING
NCT01443468National Cancer Institute (NCI)Started 2012-01-17
Rectal Neoplasms

MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer

RECRUITING
NCT03714490Phase PHASE2Cancer Institute and Hospital, Chinese Academy of Medical SciencesStarted 2018-10-23
SCPRTCRTCAPOX
Gynecological Tumors

Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors.

RECRUITING
NCT06159907IRCCS San RaffaeleStarted 2021-10-27
the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors
Uroepithelial Carcinoma

Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma

NOT YET RECRUITING
NCT06663735The First Affiliated Hospital of Xinxiang Medical CollegeStarted 2024-10-30
Metastatic Pancreatic Cancer

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

ACTIVE NOT RECRUITING
NCT02340117Phase PHASE2SynerGene Therapeutics, Inc.Started 2015-01
SGT-53nab-paclitaxelGemcitabine
Medulloblastoma RecurrentMedulloblastoma, Childhood, RecurrentMedulloblastoma, SHH-activated and TP53 Mutant

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

RECRUITING
NCT07242963Mohammad H. Abu ArjaStarted 2025-09-30
Chronic Lymphocytic Leukemia

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

RECRUITING
NCT05197192Phase PHASE3German CLL Study GroupStarted 2022-04-19
ObinutuzumabVenetoclaxAcalabrutinib